HK Stock MarketDetailed Quotes

01501 INT MEDICAL

Watchlist
  • 28.300
  • -1.600-5.35%
Market Closed Oct 18 16:08 CST
4.98BMarket Cap25.75P/E (TTM)

INT MEDICAL Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(Q6)Jun 30, 2024
(FY)Dec 31, 2023
(Q6)Jun 30, 2023
(FY)Dec 31, 2022
(Q6)Jun 30, 2022
(FY)Dec 31, 2021
(Q6)Jun 30, 2021
(FY)Dec 31, 2020
(Q6)Jun 30, 2020
(FY)Dec 31, 2019
Turnover
15.47%392.32M
28.50%752.84M
50.86%339.76M
26.08%585.88M
24.70%225.22M
29.64%464.68M
5.10%180.61M
25.12%358.43M
--171.84M
41.07%286.46M
Operating income
15.47%392.32M
28.50%752.84M
50.86%339.76M
26.08%585.88M
24.70%225.22M
29.64%464.68M
5.10%180.61M
25.12%358.43M
171.84M
41.07%286.46M
Cost of sales
-4.40%-145.55M
-24.22%-314.77M
-37.77%-139.41M
-34.12%-253.4M
-56.46%-101.19M
-52.35%-188.93M
-11.47%-64.68M
-10.71%-124.01M
---58.02M
-32.31%-112.02M
Operating expenses
-4.40%-145.55M
-24.22%-314.77M
-37.77%-139.41M
-34.12%-253.4M
-56.46%-101.19M
-52.35%-188.93M
-11.47%-64.68M
-10.71%-124.01M
-58.02M
-32.31%-112.02M
Gross profit
23.17%246.77M
31.76%438.07M
61.54%200.35M
20.58%332.49M
6.98%124.02M
17.63%275.75M
1.86%115.94M
34.38%234.42M
113.82M
47.34%174.44M
Selling expenses
-1.77%-33.61M
-19.51%-67.4M
-52.00%-33.02M
-87.85%-56.39M
-61.89%-21.72M
-39.79%-30.02M
-5.19%-13.42M
10.37%-21.48M
---12.76M
-36.13%-23.96M
Administrative expenses
-51.75%-55.22M
-54.65%-99.43M
-28.17%-36.39M
-31.07%-64.29M
-37.16%-28.39M
-36.38%-49.05M
-8.48%-20.7M
-5.24%-35.97M
---19.08M
-66.67%-34.18M
Research and development expenses
-9.54%-70.75M
-26.31%-125.85M
-70.30%-64.59M
-10.76%-99.63M
15.83%-37.93M
-39.26%-89.96M
-49.10%-45.06M
-109.96%-64.59M
---30.22M
-39.22%-30.76M
Impairment and provision
35.55%652K
56.00%-407K
175.51%481K
-63.14%-925K
-2,023.33%-637K
-1,388.64%-567K
-130.77%-30K
109.52%44K
---13K
-81.08%21K
-Other impairment is provision
35.55%652K
56.00%-407K
175.51%481K
-63.14%-925K
-2,023.33%-637K
-1,388.64%-567K
-130.77%-30K
109.52%44K
---13K
-81.08%21K
Special items of operating profit
5.03%23.94M
-2.09%33.33M
4.51%22.79M
-32.15%34.04M
-7.00%21.81M
102.70%50.17M
-5.50%23.45M
-12.14%24.75M
--24.82M
190.62%28.17M
Operating profit
24.72%111.78M
22.74%178.32M
56.82%89.62M
-7.06%145.29M
-5.03%57.15M
13.96%156.32M
-21.40%60.18M
20.61%137.18M
76.57M
67.26%113.74M
Financing cost
14.36%-1.03M
-290.46%-3.19M
-274.22%-1.21M
-29.23%-818K
-2.22%-322K
-588.04%-633K
-556.25%-315K
94.96%-92K
---48K
-19.52%-1.83M
Earning before tax
25.26%110.75M
21.22%175.13M
55.58%88.42M
-7.21%144.47M
-5.07%56.83M
13.57%155.69M
-21.77%59.86M
22.49%137.09M
76.52M
68.36%111.91M
Tax
-46.25%-11.57M
-105.92%-21.9M
-18.02%-7.91M
30.24%-10.64M
21.77%-6.7M
25.88%-15.25M
27.48%-8.57M
-33.75%-20.57M
---11.82M
-86.69%-15.38M
After-tax profit from continuing operations
23.19%99.18M
14.49%153.23M
60.61%80.51M
-4.71%133.83M
-2.28%50.13M
20.54%140.45M
-20.72%51.29M
20.70%116.52M
64.7M
65.77%96.54M
Earning after tax
23.19%99.18M
14.49%153.23M
60.61%80.51M
-4.71%133.83M
-2.28%50.13M
20.54%140.45M
-20.72%51.29M
20.70%116.52M
64.7M
65.77%96.54M
Minority profit
-45,433.33%-1.36M
-252.31%-3.23M
100.42%3K
184.29%2.12M
-203.92%-716K
48.00%-2.52M
125.59%689K
-57.10%-4.84M
---2.69M
-1,332.09%-3.08M
Profit attributable to shareholders
24.89%100.54M
18.79%156.46M
58.34%80.5M
-7.87%131.71M
0.47%50.84M
17.80%142.96M
-24.91%50.61M
21.82%121.35M
67.39M
70.42%99.61M
Basic earnings per share
20.83%0.58
16.46%0.92
54.84%0.48
-8.14%0.79
3.33%0.31
17.81%0.86
-26.83%0.3
-7.59%0.73
0.41
16.18%0.79
Diluted earnings per share
23.40%0.58
17.95%0.92
56.67%0.47
-9.30%0.78
0.00%0.3
17.81%0.86
-26.83%0.3
-7.59%0.73
0.41
16.18%0.79
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
Audit Opinions
--
Unqualified Opinion
--
Unqualified Opinion
--
Unqualified Opinion
--
Unqualified Opinion
--
Unqualified Opinion
Auditor
--
KPMG Huazhen Certified Public Accountants (Special General Partnership)
--
Lixin Certified Public Accountants (Special General Partnership)
--
Lixin Certified Public Accountants (Special General Partnership)
--
Lixin Certified Public Accountants (Special General Partnership)
--
Lixin Certified Public Accountants (Special General Partnership)
(Q6)Jun 30, 2024(FY)Dec 31, 2023(Q6)Jun 30, 2023(FY)Dec 31, 2022(Q6)Jun 30, 2022(FY)Dec 31, 2021(Q6)Jun 30, 2021(FY)Dec 31, 2020(Q6)Jun 30, 2020(FY)Dec 31, 2019
Turnover 15.47%392.32M28.50%752.84M50.86%339.76M26.08%585.88M24.70%225.22M29.64%464.68M5.10%180.61M25.12%358.43M--171.84M41.07%286.46M
Operating income 15.47%392.32M28.50%752.84M50.86%339.76M26.08%585.88M24.70%225.22M29.64%464.68M5.10%180.61M25.12%358.43M171.84M41.07%286.46M
Cost of sales -4.40%-145.55M-24.22%-314.77M-37.77%-139.41M-34.12%-253.4M-56.46%-101.19M-52.35%-188.93M-11.47%-64.68M-10.71%-124.01M---58.02M-32.31%-112.02M
Operating expenses -4.40%-145.55M-24.22%-314.77M-37.77%-139.41M-34.12%-253.4M-56.46%-101.19M-52.35%-188.93M-11.47%-64.68M-10.71%-124.01M-58.02M-32.31%-112.02M
Gross profit 23.17%246.77M31.76%438.07M61.54%200.35M20.58%332.49M6.98%124.02M17.63%275.75M1.86%115.94M34.38%234.42M113.82M47.34%174.44M
Selling expenses -1.77%-33.61M-19.51%-67.4M-52.00%-33.02M-87.85%-56.39M-61.89%-21.72M-39.79%-30.02M-5.19%-13.42M10.37%-21.48M---12.76M-36.13%-23.96M
Administrative expenses -51.75%-55.22M-54.65%-99.43M-28.17%-36.39M-31.07%-64.29M-37.16%-28.39M-36.38%-49.05M-8.48%-20.7M-5.24%-35.97M---19.08M-66.67%-34.18M
Research and development expenses -9.54%-70.75M-26.31%-125.85M-70.30%-64.59M-10.76%-99.63M15.83%-37.93M-39.26%-89.96M-49.10%-45.06M-109.96%-64.59M---30.22M-39.22%-30.76M
Impairment and provision 35.55%652K56.00%-407K175.51%481K-63.14%-925K-2,023.33%-637K-1,388.64%-567K-130.77%-30K109.52%44K---13K-81.08%21K
-Other impairment is provision 35.55%652K56.00%-407K175.51%481K-63.14%-925K-2,023.33%-637K-1,388.64%-567K-130.77%-30K109.52%44K---13K-81.08%21K
Special items of operating profit 5.03%23.94M-2.09%33.33M4.51%22.79M-32.15%34.04M-7.00%21.81M102.70%50.17M-5.50%23.45M-12.14%24.75M--24.82M190.62%28.17M
Operating profit 24.72%111.78M22.74%178.32M56.82%89.62M-7.06%145.29M-5.03%57.15M13.96%156.32M-21.40%60.18M20.61%137.18M76.57M67.26%113.74M
Financing cost 14.36%-1.03M-290.46%-3.19M-274.22%-1.21M-29.23%-818K-2.22%-322K-588.04%-633K-556.25%-315K94.96%-92K---48K-19.52%-1.83M
Earning before tax 25.26%110.75M21.22%175.13M55.58%88.42M-7.21%144.47M-5.07%56.83M13.57%155.69M-21.77%59.86M22.49%137.09M76.52M68.36%111.91M
Tax -46.25%-11.57M-105.92%-21.9M-18.02%-7.91M30.24%-10.64M21.77%-6.7M25.88%-15.25M27.48%-8.57M-33.75%-20.57M---11.82M-86.69%-15.38M
After-tax profit from continuing operations 23.19%99.18M14.49%153.23M60.61%80.51M-4.71%133.83M-2.28%50.13M20.54%140.45M-20.72%51.29M20.70%116.52M64.7M65.77%96.54M
Earning after tax 23.19%99.18M14.49%153.23M60.61%80.51M-4.71%133.83M-2.28%50.13M20.54%140.45M-20.72%51.29M20.70%116.52M64.7M65.77%96.54M
Minority profit -45,433.33%-1.36M-252.31%-3.23M100.42%3K184.29%2.12M-203.92%-716K48.00%-2.52M125.59%689K-57.10%-4.84M---2.69M-1,332.09%-3.08M
Profit attributable to shareholders 24.89%100.54M18.79%156.46M58.34%80.5M-7.87%131.71M0.47%50.84M17.80%142.96M-24.91%50.61M21.82%121.35M67.39M70.42%99.61M
Basic earnings per share 20.83%0.5816.46%0.9254.84%0.48-8.14%0.793.33%0.3117.81%0.86-26.83%0.3-7.59%0.730.4116.18%0.79
Diluted earnings per share 23.40%0.5817.95%0.9256.67%0.47-9.30%0.780.00%0.317.81%0.86-26.83%0.3-7.59%0.730.4116.18%0.79
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards HKASHKASHKASHKASHKASHKASHKASHKASHKASHKAS
Audit Opinions --Unqualified Opinion--Unqualified Opinion--Unqualified Opinion--Unqualified Opinion--Unqualified Opinion
Auditor --KPMG Huazhen Certified Public Accountants (Special General Partnership)--Lixin Certified Public Accountants (Special General Partnership)--Lixin Certified Public Accountants (Special General Partnership)--Lixin Certified Public Accountants (Special General Partnership)--Lixin Certified Public Accountants (Special General Partnership)

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
% Chg

No Data